Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated May 13, 2026·v1

Empagliflozin

Empagliflozin is a selective SGLT2 inhibitor used to manage type 2 diabetes, heart failure (regardless of ejection fraction), and chronic kidney disease. It provides significant cardiorenal protection by reducing intraglomerular pressure and improving myocardial efficiency. Key safety considerations include genital mycotic infections, volume depletion, and the risk of euglycemic DKA.

High Evidence80 references·834 words·4 min read·v1
SGLT2 inhibitorsHeart FailureChronic Kidney DiseaseType 2 DiabetesCardioprotection

Quick Reference

RxDrug of choiceFirst-line SGLT2 inhibitor for HFrEF, HFpEF, and CKD progression.
AltAlternatives[[Dapagliflozin]], [[Canagliflozin]], [[Sotagliflozin]].
⊘AvoidHypersensitivity, 2nd/3rd trimester pregnancy, lactation, and patients on dialysis.
DxTest of choiceBaseline eGFR and volume status assessment.
ScKey score[[NYHA Class]] for heart failure; [[KDIGO]] staging for CKD.
→When to referSuspected Fournier's gangrene, refractory euglycemic DKA, or eGFR decline >30% from baseline.
A foundational cardiorenal protective agent that reduces cardiovascular mortality and slows renal decline independently of its glucose-lowering effects.
Empagliflozin is a potent, highly selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) that has redefined the management of metabolic, cardiovascular, and renal diseases. By blocking glucose reabsorption in the proximal convoluted tubule, it induces controlled glucosuria and natriuresis, lowering the renal threshold for glucose independently of insulin secretion. Beyond its primary role in glycemic control for type 2 diabetes, empagliflozin exerts profound organ-protective effects, significantly reducing the risk of cardiovascular death and heart failure hospitalizations while slowing the progression of chronic kidney disease.

Overview and Recommendations

Key Facts

  • •Empagliflozin functions as a selective inhibitor of the (SGLT2) located in the S1 segment of the proximal convoluted tubule. By blocking the reabsorption of approximately 90% of filtered glucose, it promotes the excretion of 64–78 g of glucose per day in the urine, effectively lowering plasma glucose levels without increasing the risk of hyperinsulinemia or weight gain.
  • •The therapeutic paradigm for empagliflozin shifted from simple glycemic control to comprehensive organ protection following the landmark trial (2015). This trial demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease, establishing the drug as a primary agent for reducing major adverse cardiovascular events (MACE).
  • •Renal protection is achieved through the restoration of tubuloglomerular feedback, a mechanism often impaired in diabetes. By increasing sodium delivery to the macula densa, empagliflozin triggers afferent arteriolar vasoconstriction, which reduces intraglomerular hypertension and hyperfiltration, thereby preserving long-term nephron integrity as evidenced in the trial.
  • •Cardioprotective benefits extend across the entire spectrum of heart failure, including both reduced (HFrEF) and preserved (HFpEF) ejection fractions. Landmark trials such as and confirmed that empagliflozin reduces the combined risk of cardiovascular death or hospitalization for heart failure by approximately 21–25%, regardless of the patient's diabetic status.
  • •Metabolic and cellular effects include a shift in myocardial fuel utilization toward ketone bodies, which are more oxygen-efficient than fatty acids, and the activation of the pathway. These shifts promote cellular autophagy, reduce oxidative stress, and mitigate iron-dependent cell death ( ), providing a multi-layered defense against progressive ventricular remodeling and diabetic cardiomyopathy.

Clinical Use

  • •Assess renal function via (eGFR) and evaluate volume status prior to initiation. In patients with clinical evidence of volume depletion, such as those on high-dose or the elderly, volume status must be corrected before the first dose to minimize the risk of symptomatic hypotension or acute kidney injury.
  • •Initiate therapy for at a starting dose of 10 mg orally once daily, taken in the morning with or without food. If additional glycemic control is required and the 10 mg dose is well-tolerated, the dosage may be increased to a maximum of 25 mg once daily in both adults and pediatric patients aged 10 years and older.
  • •Administer a fixed dose of 10 mg once daily for the management of (HFrEF or HFpEF) and (CKD). While the glucose-lowering efficacy of empagliflozin diminishes as renal function declines, its cardiorenal protective benefits persist; it is currently indicated for initiation in CKD patients with an eGFR as low as 20 mL/min/1.73 m².
  • •Anticipate an acute, transient "dip" in eGFR of approximately 2–4 mL/min/1.73 m² within the first 4 weeks of therapy. This shift is hemodynamically mediated, reflecting the desired reduction in intraglomerular pressure, and is not indicative of structural kidney injury; long-term therapy eventually stabilizes the eGFR slope compared to placebo.
  • •Monitor for when adding empagliflozin to regimens containing or insulin secretagogues like . Clinicians should consider a preemptive dose reduction of the background insulin-stimulating agent to maintain glycemic safety while the SGLT2 inhibitor is titrated.
  • •Withhold empagliflozin for at least 3 days prior to major elective surgery or any procedure requiring prolonged fasting. This "surgical pause" is essential to mitigate the risk of SGLT2-inhibitor-associated , which can occur even with near-normal blood glucose levels (euglycemic DKA).
  • •Resume therapy only after the patient is hemodynamically stable, has resumed normal oral intake, and the risk of metabolic stress has subsided. Glucosuria can persist for several days after the last dose, so monitoring for delayed DKA symptoms is prudent in the postoperative period.

Safety

  • •Counsel patients regarding the increased risk of genital mycotic infections, such as in women and balanitis in men, which occur in approximately 5–6% of patients. These infections are typically mild and can be managed with standard antifungal treatments without requiring the permanent discontinuation of empagliflozin.
  • •Maintain a high index of suspicion for euglycemic (DKA), characterized by metabolic acidosis with blood glucose levels typically below 250 mg/dL. Patients presenting with nausea, vomiting, or abdominal pain should be screened for ketones in the blood or urine regardless of their blood sugar reading.
  • •Monitor for symptomatic and volume depletion, particularly in patients aged 75 years or older, those with a baseline eGFR < 60 mL/min/1.73 m², or those using . The drug's mild diuretic effect can lead to orthostatic changes and transient increases in serum creatinine if volume status is not carefully managed.
  • •Educate patients on the rare but severe risk of (necrotizing fasciitis of the perineum). Any report of perineal pain, tenderness, erythema, or swelling accompanied by fever or malaise requires immediate drug cessation and urgent surgical evaluation.
  • •Avoid the use of empagliflozin during the second and third trimesters of pregnancy and during lactation. Animal models indicate that exposure during periods of renal maturation can cause permanent structural damage to the fetal kidneys, including pelvic and tubule dilatations.
  • •Monitor serum levels closely during initiation and titration, as SGLT2 inhibitors may increase renal lithium clearance and lead to subtherapeutic lithium concentrations. Dose adjustments of lithium may be necessary to maintain psychiatric stability.
  • •Advise patients that empagliflozin will cause a positive urine glucose test due to its primary mechanism of action. Alternative methods, such as or fingerstick glucose monitoring, should be used to assess glycemic control rather than urine-based assays.

Board Review — High Yield

  • •Mechanism — Inhibits SGLT2 in the proximal tubule, causing glucosuria and natriuresis.
  • •eGFR Dip — A transient 2-4 mL/min/1.73 m² decline upon initiation is hemodynamic and protective, not toxic.
  • •Euglycemic DKA — Metabolic acidosis occurring with blood glucose < 250 mg/dL; requires high clinical suspicion.
  • •Fournier's Gangrene — Rare but life-threatening necrotizing fasciitis of the perineum associated with SGLT2 inhibitors.
  • •EMPA-REG OUTCOME — Landmark trial showing reduced CV death in T2DM patients with established CV disease.
  • •Surgical Pause — Must stop the drug 3 days before major surgery to prevent perioperative DKA.
  • •Tubuloglomerular Feedback — Restored by SGLT2i, leading to afferent arteriolar vasoconstriction and reduced glomerular pressure.

Deep Dive — Evidence Details

References

  1. [1]

    Kongmalai T, Hadnorntun P, Leelahavarong P et al.. “Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2023). PMID: 38179304 ↗

    L1SR_MA_RCTCited in: Introduction and Chemical Structure
  2. [2]

    Bonilha I, Yoshinaga MY, Chaves-Filho AB et al.. “LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial.” Atherosclerosis (2026). PMID: 41806515 ↗

    L1RCTCited in: Introduction and Chemical Structure, Indications and Clinical Use, Adverse Effects and Toxicity
  3. [3]

    Murugavel S, Retnakaran R, Feig DS et al.. “Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.” Diabetes, obesity & metabolism (2025). PMID: 40964955 ↗

    L1RCTCited in: Introduction and Chemical Structure, Special Populations and Contraindications
  4. [4]

    Bauer KI, Baker D, Lerner R et al.. “Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial.” Cardiovascular diabetology (2025). PMID: 40922034 ↗

    L1RCTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  5. [5]

    Agarwal R, Green JB, Heerspink HJL et al.. “COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39916475 ↗

    L5RCTCited in: Introduction and Chemical Structure
  6. [6]

    Packer M, Ferreira JP, Butler J et al.. “Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.” Journal of the American College of Cardiology (2024). PMID: 39217550 ↗

    L1RCTCited in: Introduction and Chemical Structure
  7. [7]

    Yankah RK, Anku EK, Eligar V. “Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.” Journal of diabetes research (2024). PMID: 38766320 ↗

    L1SR_OBSCited in: Introduction and Chemical Structure
  8. [8]

    Kim NH, Lim S, Jeong IK et al.. “Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP).” Diabetes & metabolism journal (2025). PMID: 39756817 ↗

    L5TRIAL_NONRANDOMCited in: Introduction and Chemical Structure
  9. [9]

    Nowak-Szwed A, Eyileten C, Wicik Z et al.. “Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.” Cardiovascular diabetology (2025). PMID: 41462250 ↗

    L5RCTCited in: Mechanism of Action, Indications and Clinical Use, Adverse Effects and Toxicity
  10. [10]

    Molaei A, Molaei E, Sadeghnia H et al.. “LKB1: An emerging therapeutic target for cardiovascular diseases.” Life sciences (2022). PMID: 35907495 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  11. [11]

    Luo H, Zhang N, Liu Y et al.. “Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review.” Current vascular pharmacology (2025). PMID: 41601174 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  12. [12]

    Li YC, Chai HT, Ko SF et al.. “Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41854484 ↗

    L5OTHERCited in: Mechanism of Action
  13. [13]

    Shi X, Zou W, Li X et al.. “SGLT2 inhibition attenuates diabetic tubulopathy by suppressing SGK1-mediated pyroptosis.” Frontiers in endocrinology (2025). PMID: 41030847 ↗

    L5OTHERCited in: Mechanism of Action
  14. [14]

    Cui M, Zhang J, Wang Z et al.. “Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway.” Antioxidants & redox signaling (2026). PMID: 41002023 ↗

    L5OTHERCited in: Mechanism of Action
  15. [15]

    Zhang P, Mao C, Sun A et al.. “Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2025). PMID: 40898408 ↗

    L3OTHERCited in: Mechanism of Action
  16. [16]

    Hoehlschen J, Gosset É, Hofreither D et al.. “Heart saver: Comprehensive investigation of (redox-) proteomic and thiol metabolite changes induced by Cana-, Dapa-, Empagliflozin treatment in 2D and 3D heart cell models reveals increased mitochondrial activity and glutathione redox defense and involvement of redox signaling.” Life sciences (2025). PMID: 40840617 ↗

    L5OTHERCited in: Mechanism of Action
  17. [17]

    Hu X, Li D, Chen W et al.. “Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical "2-Hit" Model Reveals Autophagy Enhancement Via AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway.” Journal of the American Heart Association (2025). PMID: 40767292 ↗

    L5OTHERCited in: Mechanism of Action
  18. [18]

    Han Z, Han S, Fang X et al.. “Acetyl-CoA carboxylase activation disrupts iron homeostasis to drive ferroptosis.” Free radical biology & medicine (2025). PMID: 40449808 ↗

    L5OTHERCited in: Mechanism of Action
  19. [19]

    Heo YJ, Park J, Lee N et al.. “Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.” International journal of molecular sciences (2025). PMID: 40362294 ↗

    L5OTHERCited in: Mechanism of Action
  20. [20]

    Herwig M, Sieme M, Kovács A et al.. “Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features.” Cardiovascular diabetology (2025). PMID: 40361188 ↗

    L4OTHERCited in: Mechanism of Action
  21. [21]

    Ferrannini E, Baldi S, Frascerra S et al.. “Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.” Diabetes (2016). PMID: 26861783 ↗

    L2RCTCited in: Pharmacokinetics (LADME)
  22. [22]

    Brand T, Macha S, Mattheus M et al.. “Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.” Advances in therapy (2012). PMID: 23054692 ↗

    L2RCTCited in: Pharmacokinetics (LADME), Drug Interactions
  23. [23]

    Ferrannini E, Muscelli E, Frascerra S et al.. “Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.” The Journal of clinical investigation (2014). PMID: 24463454 ↗

    L2TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  24. [24]

    Macha S, Rose P, Mattheus M et al.. “Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.” Diabetes, obesity & metabolism (2014). PMID: 23859534 ↗

    L2TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  25. [25]

    Macha S, Mattheus M, Halabi A et al.. “Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.” Diabetes, obesity & metabolism (2014). PMID: 23859488 ↗

    L2TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
  26. [26]

    Sarashina A, Koiwai K, Seman LJ et al.. “Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.” Drug metabolism and pharmacokinetics (2013). PMID: 23149871 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  27. [27]

    Rascher J, Cheng S, Johnston C et al.. “Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10-17 years with type 2 diabetes mellitus.” British journal of clinical pharmacology (2025). PMID: 40390307 ↗

    L2RCTCited in: Pharmacokinetics (LADME), Dose and Administration, Special Populations and Contraindications
  28. [28]

    Chen G, Zhang D, Du A et al.. “Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study.” Pharmacotherapy (2020). PMID: 32498113 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  29. [29]

    Macha S, Brand T, Meinicke T et al.. “Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.” Clinical therapeutics (2015). PMID: 26138865 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  30. [30]

    Zhao X, Cui Y, Zhao S et al.. “Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.” Clinical therapeutics (2015). PMID: 26101175 ↗

    L1RCTCited in: Pharmacokinetics (LADME)
  31. [31]

    Macha S, Mattheus M, Pinnetti S et al.. “Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.” Clinical therapeutics (2015). PMID: 26051874 ↗

    L1RCTCited in: Pharmacokinetics (LADME), Drug Interactions
  32. [32]

    Heise T, Mattheus M, Woerle HJ et al.. “Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.” Clinical therapeutics (2015). PMID: 25636696 ↗

    L1RCTCited in: Pharmacokinetics (LADME), Drug Interactions
  33. [33]

    AlHussaini KI. “Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in medicine (2025). PMID: 41717349 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics
  34. [34]

    Lin R, Hsu CL, Shih MC et al.. “Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.” Diabetes, obesity & metabolism (2026). PMID: 41147324 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics, Indications and Clinical Use
  35. [35]

    Lim S, Kim TN, Mok JO et al.. “Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial.” Diabetes, obesity & metabolism (2026). PMID: 41883295 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  36. [36]

    Gashaw IA, Tuttle KR, Monroy Kuhn M et al.. “Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.” European journal of endocrinology (2026). PMID: 41436034 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification
  37. [37]

    Lee SH, Han KA, Hong EG et al.. “Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.” Diabetes, obesity & metabolism (2026). PMID: 41417560 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  38. [38]

    Seo DH, Min KW, Sohn HS et al.. “Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41236870 ↗

    L1RCTCited in: Pharmacodynamics, Adverse Effects and Toxicity
  39. [39]

    Hassan Waseem M, Abideen ZU, Shoaib A et al.. “Comparing Efficacy and Safety of Different Aldosterone Synthase Inhibitors for Hypertension: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.” Clinical Medicine Insights. Cardiology (2026). PMID: 41993949 ↗

    L1SR_MA_RCTCited in: Pharmacodynamics
  40. [40]

    Okita S, Kitahara H, Shoji M et al.. “Evaluation of the efficacy of empagliflozin in patients with preserved left ventricular ejection fraction undergoing transcatheter aortic valve implantation for aortic stenosis: protocol for a randomised, open-label, controlled study.” BMJ open (2026). PMID: 42082222 ↗

    L5TRIAL_NONRANDOMCited in: Pharmacodynamics
  41. [41]

    Delic D, Gashaw I, Duran-Fernandez I et al.. “Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.” International journal of molecular sciences (2025). PMID: 41303298 ↗

    L2TRIAL_NONRANDOMCited in: Pharmacodynamics
  42. [42]

    Zhu X, Wang X, Zhang P et al.. “Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987895 ↗

    L1SR_OBSCited in: Pharmacodynamics
  43. [43]

    Su AY, Csere MM, Shan R et al.. “Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.” Diabetes research and clinical practice (2025). PMID: 40324721 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  44. [44]

    Wong SY, Chan SC, Mo YF et al.. “Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial.” Schizophrenia bulletin (2026). PMID: 42104798 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  45. [45]

    Nesti L, Santoni L, Baldi S et al.. “Exercise Metabolic Flexibility in Type 2 Diabetes Treated With Empagliflozin: An Exploratory Analysis of the Randomised Trial EMPA-HEART.” Diabetes, obesity & metabolism (2026). PMID: 41918256 ↗

    L2RCTCited in: Indications and Clinical Use
  46. [46]

    Cliff CL, Shah MU, Ward JK et al.. “Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes.” Cardiovascular diabetology (2026). PMID: 41680826 ↗

    L2RCTCited in: Indications and Clinical Use, Dose and Administration, Adverse Effects and Toxicity
  47. [47]

    Makino H, Kasahara M, Takashima R et al.. “Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41582689 ↗

    L1RCTCited in: Indications and Clinical Use
  48. [48]

    Calvigioni M, Biancalana E, Rossi C et al.. “Effect of SGLT2 Inhibitors + DPP-4 Inhibitors on Urine Microbiota in Type 2 Diabetes.” Diabetes/metabolism research and reviews (2026). PMID: 41566786 ↗

    L1RCTCited in: Indications and Clinical Use
  49. [49]

    Ferreira JP, Packer M, Butler J et al.. “Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-Preserved.” JACC. Heart failure (2026). PMID: 41493412 ↗

    L2RCTCited in: Indications and Clinical Use
  50. [50]

    Agarwal R, Green JB, Heerspink HJL et al.. “Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.” Journal of the American College of Cardiology (2026). PMID: 41493296 ↗

    L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  51. [51]

    Yu D, Zou M, Cheng B et al.. “Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 41485450 ↗

    L1RCTCited in: Indications and Clinical Use
  52. [52]

    Refardt J, Imber C, Sailer CO et al.. “A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32019783 ↗

    L1RCTCited in: Dose and Administration
  53. [53]

    Wanner C, Heerspink HJL, Zinman B et al.. “Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.” Journal of the American Society of Nephrology : JASN (2018). PMID: 30314978 ↗

    L1RCTCited in: Dose and Administration
  54. [54]

    Yoshikawa F, Kumashiro N, Shigiyama F et al.. “Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial.” Diabetes, obesity & metabolism (2019). PMID: 30187632 ↗

    L1RCTCited in: Dose and Administration
  55. [55]

    DeFronzo RA, Lee C, Kohler S. “Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.” Advances in therapy (2018). PMID: 29949041 ↗

    L1RCTCited in: Dose and Administration
  56. [56]

    Shimada A, Hanafusa T, Yasui A et al.. “Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.” Diabetes, obesity & metabolism (2018). PMID: 29766633 ↗

    L1RCTCited in: Dose and Administration, Dose Modification
  57. [57]

    Laffel LMB, Tamborlane WV, Yver A et al.. “Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.” Diabetic medicine : a journal of the British Diabetic Association (2018). PMID: 29655290 ↗

    L1RCTCited in: Dose and Administration, Dose Modification, Special Populations and Contraindications
  58. [58]

    Inzucchi SE, Zinman B, Fitchett D et al.. “How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.” Diabetes care (2018). PMID: 29203583 ↗

    L1RCTCited in: Dose and Administration
  59. [59]

    Uster A, Desai N, Navaneethan SD et al.. “Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.” Clinical therapeutics (2025). PMID: 41047325 ↗

    L1RCTCited in: Dose Modification, Adverse Effects and Toxicity
  60. [60]

    Mancia G, Cannon CP, Tikkanen I et al.. “Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.” Hypertension (Dallas, Tex. : 1979) (2016). PMID: 27977392 ↗

    L1RCTCited in: Dose Modification
  61. [61]

    Hadjadj S, Rosenstock J, Meinicke T et al.. “Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 27493136 ↗

    L1RCTCited in: Dose Modification
  62. [62]

    Yoon KH, Nishimura R, Lee J et al.. “Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.” Diabetes, obesity & metabolism (2016). PMID: 27265507 ↗

    L1RCTCited in: Dose Modification
  63. [63]

    Chilton R, Tikkanen I, Cannon CP et al.. “Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.” Diabetes, obesity & metabolism (2015). PMID: 26343814 ↗

    L1RCTCited in: Dose Modification
  64. [64]

    Kovacs CS, Seshiah V, Merker L et al.. “Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.” Clinical therapeutics (2015). PMID: 26138864 ↗

    L2RCTCited in: Dose Modification
  65. [65]

    Kohler S, Zeller C, Iliev H et al.. “Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.” Advances in therapy (2017). PMID: 28631216 ↗

    L1TRIAL_NONRANDOMCited in: Dose Modification
  66. [66]

    Mottl A, Scott C, Green JB et al.. “Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.” Journal of the American Society of Nephrology : JASN (2026). PMID: 41196655 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  67. [67]

    Agarwal R, Green JB, Heerspink HJL et al.. “Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).” Diabetes care (2025). PMID: 40968755 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  68. [68]

    Lei Y, Yi Q, Ji S et al.. “Bioequivalence Evaluation of Two Metformin/Empagliflozin Fixed-Dose Combination Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Crossover Study.” Clinical pharmacology in drug development (2026). PMID: 41578725 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  69. [69]

    Lim S, Park CY, Jeong IK et al.. “Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study.” Journal of diabetes and its complications (2026). PMID: 41223492 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  70. [70]

    Yee KM, Sagim E, Leong CW et al.. “Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy Volunteers.” Clinical pharmacology in drug development (2026). PMID: 41077870 ↗

    L1RCTCited in: Adverse Effects and Toxicity
  71. [71]

    Carbone S, Canada JM, Billingsley HE et al.. “Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.” Diabetes, obesity & metabolism (2018). PMID: 29603546 ↗

    L4TRIAL_NONRANDOMCited in: Drug Interactions
  72. [72]

    Packer M, Anker SD, Butler J et al.. “Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.” Journal of the American College of Cardiology (2021). PMID: 33736819 ↗

    L1RCTCited in: Drug Interactions
  73. [73]

    Kim D, Choi M, Jin BH et al.. “Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers.” Clinical and translational science (2023). PMID: 37282359 ↗

    L1RCTCited in: Drug Interactions
  74. [74]

    Lee M, Hong S, Cho Y et al.. “Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.” BMC medicine (2025). PMID: 40336058 ↗

    L1RCTCited in: Drug Interactions
  75. [75]

    Ferreira JP, Zannad F, Pocock SJ et al.. “Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.” Journal of the American College of Cardiology (2021). PMID: 33736821 ↗

    L1RCTCited in: Drug Interactions
  76. [76]

    Lava SAG, Laurence C, Di Deo A et al.. “Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review.” Paediatric drugs (2024). PMID: 38635113 ↗

    L1SR_OBSCited in: Special Populations and Contraindications
  77. [77]

    Laffel LM, Danne T, Klingensmith GJ et al.. “Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.” The lancet. Diabetes & endocrinology (2023). PMID: 36738751 ↗

    L1RCTCited in: Special Populations and Contraindications
  78. [78]

    Furth SL. “Trials and Tribulations - The Challenges of Clinical Trials in Children.” NEJM evidence (2023). PMID: 38320507 ↗

    L5TRIAL_NONRANDOMCited in: Special Populations and Contraindications
  79. [79]

    Gross O, Boeckhaus J, Weber LT et al.. “Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39122650 ↗

    L5TRIAL_NONRANDOMCited in: Special Populations and Contraindications
  80. [80]

    Sailer MO, Neubacher D, Johnston C et al.. “Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial.” Therapeutic innovation & regulatory science (2025). PMID: 39373938 ↗

    L2RCTCited in: Special Populations and Contraindications

Revision History

All updates applied to this page

Loading revisions…